ADMA - ADMA Biocenters receives FDA approval for eighth plasma collection center
- ADMA Biologics ( NASDAQ: ADMA ) it had received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond.
- The facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.
- "With eight FDA-licensed plasma collection centers, we are well on our way to achieving our stated corporate objective of having a total of ten FDA-approved plasma collection centers, collecting normal source plasma and Respiratory Syncytial Virus (“RSV”) hyperimmune plasma, by year-end 2023," said Brian Lenz, Chief Financial Officer .
- ( ADMA ) rises 1% before the bell.
For further details see:
ADMA Biocenters receives FDA approval for eighth plasma collection center